Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III ...

A review of recent trends and remaining challenges in bispecific antibody (bsAb) production has been published.

Novo Nordisk has bolstered the case for its near-approval hemophilia A drug candidate Mim8, linking the prospect to ...

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bispecifics ...

Zenocutuzumab is a novel bispecific antibody designed by Merus, N.V. In a multicenter global phase 2 clinical trial led by MSK gynecologic medical oncologist and early drug development specialist ...

Recombinant antibodies are invented antibodies formed by using recombinant DNA technology. While traditional monoclonal ...

ORION CORPORATION PRESS RELEASE 30 JANUARY 2025 at 16.00 EET Orion and Invenra announce discovery service and commercial ...

In this video, Sham Mailankody, MBBS discusses the current state of the pipeline for developing multiple myeloma treatments.

Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

BioNTech SE (“BioNTech”) confirmed the completion of its acquisition of biotechnology company Biotheus for an upfront payment ...